ABSTRACT Recent advances in molecular biology, genomics, and immunology are revolutionizing our approach to managing infectious diseases of humans, livestock, and poultry. One of the most interesting additions to the armamentarium of research focusing on controlling infectious diseases has been a better understanding of how the host's innate immune system recognizes "danger" signals. Additionally, there has been recognition of the relationship between the innate and the specific arms of the immune system. For example, the recent discovery that CpG motifs can modulate immune responses has been used both as an adjuvant to enhance the responses to vaccines, as well as a direct immunostimulant to prevent
INTRODUCTION
Immunization against infectious diseases has proven to be one of the most cost-effective methods of controlling economic losses in livestock and poultry. Unfortunately, even though such practices have been around for over 200 yr, animals and humans continue to suffer from a large number of infectious disease outbreaks. These losses occur as a result of different management conditions, as well as the possible ineffectiveness of the vaccines employed. For example, in poultry, many infectious agents, including Marek's disease, can infect chickens at a very young age. Unfortunately, it generally takes at least 1 to 2 wk following vaccination for protection to develop; therefore, even if chicks are vaccinated at hatching, there is insufficient time between immunization and exposure to prevent clinical disease. To overcome this problem, the industry has resorted to in ovo vaccination (Gagic et al., 1999) . Although immunization 3 d before hatching helps to "close the window" of susceptibility, immunity to the vaccine is not at peak levels at birth or at the time of initial infection. As a result, some birds 2003 Poultry Science Association, Inc. Received for publication August 28, 2002 . Accepted for publication January 27, 2003. 1 To whom correspondence should be addressed: babiuk@sask. usask.ca.
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infections. Using an Escherichia coli chicken model, we have been able to prevent cellulitis in chickens with CpG alone. Thus, CpG can be used immunoprophylactically to reduce infectious diseases. In addition, we will describe how CpG formulations with various antigens; recombinant proteins, peptides, and conventional vaccines can enhance immune responses to each of these different vaccine combinations. What is even more interesting is that CpG incorporation in vaccines can shift the immune response from a predominant T helper 2 (Th2)-like immune response generally induced by killed or subunit proteins to a much more balanced Th1-Th2 response. These immunomodulatory effects have significant implications for management of infectious diseases of all vertebrates. become infected. To circumvent these problems, it would be great if it was possible to provide rapid protection at hatching, possibly by stimulating the innate immune system with immunomodulators combined with vaccines to provide both early and long-term protection.
The recent discovery that molecules like cytosine phosphoric acid and guanidine (CpG) can stimulate innate immunity and induce protection to a number of pathogens within 1 or 2 d following CpG treatment has created new opportunities for enhancing disease resistance in animals and poultry (Krieg et al., 1998a; Elkins et al., 1999; Klinman et al., 1999a,b) . The current review will describe some of the progress that has been made in the area of CpG and its ability to stimulate both innate and specific immunity.
Identification of CpG Motifs
Although it was over 100 yr ago that Coley used bacterial extracts to treat cancer patients, the mechanism whereby these extracts enhanced protection was not known. Approximately 15 yr ago, Tokunaga et al. (1984) first recognized that bacterial DNA could activate innate immune defenses and that the presence of bacterial DNA Abbreviation Key: CpG = cytosine phosphoric acid and guanidine; Th1 = T helper 1; Th2 = T helper 2; TLR-(2, 4, or 9) = toll-like receptor 2, 4, or 9, respectively. in the bacterial extracts was possibly responsible, at least in part, for the effects observed earlier by Coley.
Subsequently, Krieg et al. (1995) demonstrated that mammalian cells recognize CpG dinucleotide motifs and respond by orchestrating various intracellular signaling to these perceived "danger" signals. These initial observations were extended to try and explain why mammalian cells recognize these motifs and why mammalian DNA does not normally stimulate these same signaling events. As a result of detailed investigations, it was found that the upstream and downstream nucleotides of CpG motifs are critical for stimulating vertebrate immune cells (Krieg and Davis, 2001 ). Not only is the frequency of CpG sequences higher in bacterial DNA than in mammalian DNA, the upstream nucleotide in mammalian DNA are generally different. In mammalian cells, a C is present upstream and a G downstream of a CpG sequence. This specific configuration of the motif results in suppression of the stimulatory properties of CpG. Secondly, the C nucleotide is methylated in mammalian DNA, but not in bacterial DNA, also reducing or inhibiting the immunostimulatory properties (Krieg et al., 1998a,b) .
Investigations of the "danger" recognition pathway of the immune system has led to the identification of various pattern recognition receptors on mammalian cells. Following the interaction of mammalian cells with specific stimuli such as lipopolysaccharide, peptidoglycan, or CpG with these pathogen-associated ligands results in stimulation of signal transduction pathways in the cell and subsequent stimulation of innate immunity (Hacker et al., 2000) . Many of these host cell ligands are regulated and are members of the toll-like receptor (TLR) family (Medzhitov and Janeway, 2000; Aderem and Ulevitch, 2002) . Each specific bacterial product appears to bind to a specific member of the TLR family. For example, TLR-2 binds peptidoglycan, whereas TLR-4 recognizes lipopolysaccharide. Recent studies have shown that CpG also binds to this family of receptors, more specifically, TLR-9 (Hemmi et al., 2000) . Currently, there are TLR-9 knockout mice to study the effect of TLR-9 stimulation by CpG in vivo in concert with all of the components of the immune systems (Hacker et al., 2000) . These knockout mice are becoming extremely valuable to demonstrate the role of TLR-9 in CpG modulation of the immune system and in studying the mechanisms of CpG signaling. Similarly, transfection of TLR-9 negative cells with TLR-9 will allow a dissection of signaling pathways that are unique to CpG.
Innate Immune Responses
The innate immune system is one of the earliest defense mechanisms triggered upon exposure to any infectious agent. It is the effectiveness of this arm of the immune system that will often determine whether an infectious agent becomes established or not. Indeed, there are numerous reports in the literature describing the importance of innate immunity in resistance to infection (Vogels and van der Meer, 1992; Hadden, 1993; Fearon and Locksley, 1996) .
To investigate the potential of CpG in stimulating innate immunity and in providing protection against infection, a number of viral, bacterial, and parasitic models have been used to date (Klinman et al., 1999a) . In all of these reported cases, the investigators used intracellular pathogens as model systems. Analysis of the kinetics of protection demonstrated that protection occurred within hours to days of exposure to CpG and lasted for at least 2 wk (Krieg et al., 1998a; Oxenius et al., 1999) . Repeated administration did not result in toxological events but extended the duration of protection. These later observations are critical because they demonstrate the safety of CpG as a therapeutic agent. Further support for its safety come from studies where doses as high as 200 mg delivered to a cow did not induce any alterations in acute phase protein responses, temperature, or changes in peripheral blood leukocyte numbers (unpublished results).
Studies have also been reported that CpG could be administered after an infection was established. This, however, occurs in chronic diseases such as Leishmania. In the case of Leishmania, infection with the parasite often results in chronic infections and a T helper 2 (Th2) -type immune response (Zimmermann et al., 1998) . Treatment of these chronically infected individuals shifts the immune response from a Th2-to a T helper 1 (Th1) -like immune response. Coincident with the shift of the immune response is clearance of Leishmania. Thus, it is clear that depending on the pattern of pathogenesis, CpG can be given prior to or after exposure to the pathogen, with acute infections requiring pretreatment, whereas chronic infections can be treated with CpG after infection has been initiated.
Since the majority of the reported studies using CpG as an immunotherapeutic/prophylactic agent to date have been done in mice, we chose the chicken model to extend the range of hosts that might be potential targets for CpG therapy. Furthermore, we chose an extracellular pathogen, Escherichia coli, as the model infectious agent.
E. coli causes a variety of disease syndromes in poultry, including yolk sac infections, omphalitis, respiratory tract infection, swollen head syndrome, septicemia, and cellulitis (Cheville and Arp, 1978; Morley and Thomson, 1984; Randall et al., 1984) . In many cases, the bacteria can spread systemically, resulting in subacute forms of pericarditis, air sacculitis, and perihepatitis. A recently reported syndrome, cellulitis, occurs following introduction of E. coli into a skin lesion with subsequent cellular infiltration and cellulitis. This syndrome is one of the greatest causes of condemnation of carcasses at slaughter. As a result, these losses are directly transmitted to economic losses as the producers have had to maintain the birds from hatching to slaughter with no economic return. Thus, if it was possible to treat birds with a inducer of innate immunity to prevent these cellulitis lesions, this would be of significant economic importance to the poultry industry.
In an attempt to test the potential of CpG to reduce E. coli-induced cellulitis, we developed a chicken scratch model (Gomis et al., 1997) wherein we introduce E. coli into the skin of chickens in a natural manner through a Non-CpG CpG FIGURE 1. Effect of cytosine phosphoric acid and guanidine (CpG) on Escherichia coli-induced mortality in chickens. Young chicks (23 d of age) were injected subcutaneously in the left caudal abdominal region with 50 µg of CpG. Two days later, they were challenged in the same area with E. coli. Challenge was by making two parallel 3-cm-long scratches of the skin, followed by applying E. coli to the scratch using a cotton applicator. The application was repeated 15 min later. n = 40 birds per group. lesion (scratch) in the skin. As a result, the E. coli colonizes the skin at the site of the scratch resulting in cellulitis and, depending on the dose of bacteria inoculated, the bacteria can spread systemically and cause mortality. Using this model, we tested the potential for CpG to reduce both mortality and development of cellulitis lesions in young chickens (3 wk old). Delivery of high doses of E. coli to the scratches of birds resulted in high mortality, which could be dramatically reduced by pretreatment with CpG. Figure 1 clearly demonstrates that injection of 50 µg of CpG subcutaneously into the region where E. coli was introduced 48 h later had a dramatic impact on the clinical signs and mortality of the birds. In this experiment, approximately 90% of the non-CpG treated animals died, whereas only 15% of the CpG-treated animals died.
As CpG had such a dramatic effect on mortality of birds, we conducted subsequent experiments to determine the minimal dose of CpG that could provide protection. Figure 2 demonstrates that doses as low as 3.1 µg provided very significant protection. Repeated experiments with even lower doses demonstrated that protec- 
or near the site of E. coli introduction, could protect chickens from not only mortality, but the sizes of the cellulitis lesions were also eliminated or reduced dramatically.
To determine whether CpG was acting locally or had a systemic effect, we conducted a series of experiments wherein we injected CpG intramuscularly or at a distant site or subcutaneously at the site where E. coli was subsequently administered. Figure 3 demonstrates that subcutaneous administration is more efficacious than intramuscular administration; however, both groups provided significant protection as compared to the control groups. Furthermore, subcutaneous administration at a distant site also provided protection but not as dramatic as subcutaneous administration at the site of E. coli introduction (data not shown). Subcutaneous administration at a distant sight was equivalent to intramuscular delivery. These results suggest that although CpG can stimulate systemic effects, local effects are more dramatic.
To try and explain the reason for increased local effects, we conducted histological studies of the CpG injection site. This achieved a number of purposes. First, any inflammatory response, as measured by leukocyte infiltration, may be correlated with protection. If there are many cells at the site of rejection, they may prevent the establishment of the infection and thereby help explain the reason for increased survival following treatment. Second, if there was significant leukocyte infiltration, it may signal pathological changes at the injection site, which may have long-term consequences and lead to condemnation of poultry at slaughter. Figure 4 demonstrates that cellular infiltration is extremely rapid, with cells being present at the injection site within 1 d of CpG treatment, and remaining elevated for up to 10 d postadministration. However, cellular infiltration decreased dramatically by 7 and 10 d and was nondetectable by d 14 (Figure 4) . It is interesting to note that even though there was a high level of cellular infiltration at the site of injection of CpG, there was no evidence of necrosis or long-term consequence. This is critical inas- 4. Cytosine phosphoric acid and guanidine (CpG)-induced cellular infiltration. Chicks at 14 d of age were injected subcutaneously with 100 µg of CpG. Birds (three per timepoint) were euthanized on the days indicated and processed for histopathology. Tissue sections from the caudal abdominal subcutaneous tissue or drumstick were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 5-µm thickness, and stained with hematoxylin and eosin. A histological score from 0 to 4+ (0 = no visible lesions; 1+ = focal, mild mononuclear, and heterophil infiltrations or cellulitis or myositis; focal, mild; 2+ = locally extensive, moderate mononuclear and heterophil infiltrations or cellulitis or myositis; locally extensive, moderate 3+ = locally extensive, moderate to severe mononuclear and heterophil infiltrations or cellulitis or myositis; locally extensive, moderate to severe; 4+ = diffuse, severe mononuclear and heterophil infiltrations or cellulitis or myositis) was used to assess infiltration. much as any long-term granulomas or necrosis sites would result in condemnation or trimming at slaughter. A parallel experiment designed to test the duration of protection demonstrated a very good correlation between cellular infiltration/activation and protection. Thus, chickens could be protected within 1 d of CpG treatment, and by 10 to 14 d the protection was minimal or nonexistent ( Figure 5 ). These results support similar studies in mice (Rosenthal, unpublished results) in which CpG also stimulated significant cellular infiltration and protection from herpes simplex virus.
It is believed that one of the reasons that neonates are so susceptible to infection is that their immune systems may not be fully functional. To test whether CpG could stimulate cells of young animals, we used day-old chicks. Treatment of these chicks with CpG showed a dramatic FIGURE 5. Duration of protection from Escherichia coli following treatment with cytosine phosphoric acid and guanidine (CpG). Chicks were injected subcutaneously with 50 µg of CpG. At various days following treatment, they were challenged with E. coli using a scratch model. Mortality was recorded daily for 15 d postchallenge. impact on mortality following exposure to E. coli. Figure  6 shows the increased resistance to infection at different doses of E. coli. Following treatment with CpG, chicks required 2 logs more E. coli to achieve the same mortality. This translates to a 200-fold increase in resistance. Under field conditions, this could make a difference between disease and no disease.
CpG Enhancement of Specific Immunity
Previously, it was shown that specific immune responses were orchestrated by various cytokines and that cytokines could be used as adjuvants (Heath and Playfair, 1992; Hughes and Babiuk, 1992) . These observations, combined with the observation that CpG can stimulate the production of cytokines in mammalian cells, led to the suggestion that CpG might also be an effective adjuvant. This suggestion has proven to be correct, and now there are numerous reports demonstrating that CpG can act as an adjuvant in viral, bacterial, and parasitic diseases (reviewed in Krieg and Davis, 2001 ). In addition, CpG has been used to stimulate immunity to academic antigens such as ovalbumin, beta-galactoside, hen egg lysozyme, and fowl gamma globulin as well as tumor antigens. In the case of tumor antigens, immunization of the tumor antigen was often combined with a carrier to further enhance the immune response. Furthermore, CpG has been shown to even enhance immune responses to live vaccines.
Recently, we tested the adjuvant activity of CpG with over a dozen different adjuvants including mineral oils, metabolizable oils, and nonoil adjuvants such as Quil A and alum. In each case, we demonstrated that CpG could enhance immune responses over those developed by either adjuvant by themselves (Ioannou et al., unpublished) . Not only have we demonstrated that CpG can enhance immune responses if combined with a variety of antigens, we have also demonstrated its adjuvant activity with individual purified proteins, conventional killed vaccines, and peptides. The exact mechanism by which CpG acts synergistically with other adjuvants is un-known, but it appears that retaining CpG at a specific concentration at the site of immune activation may be an important factor in enhancing immune responses to the vaccines. It is possible that the formulations retain CpG at the site of injection allowing sufficient cellular infiltration to create a cytokine environment with the appropriate costimulatory molecules required for effective expansion of immune cells.
One of the main observations of all of these studies is that CpG not only acts as an excellent adjuvant, producing higher immune responses than Freund's adjuvant, but that the immune responses are more balanced with a strong Th1-like immune response. This is evident by the presence of cytotoxic T lymphocytes, interferon gamma secreting cells, and a balanced IgG 1 -IgG 2a antibody response. Another important observation of these studies is that when CpG is combined with adjuvants that normally produce a biased Th2-like immune response, CpG shifts the response to one with strong Th1-like characteristics (Chu et al., 1997; Lipford et al., 1997) . Finally, the inflammatory responses and tissue reactions at the site of vaccination are significantly lower with CpG adjuvants than with most other adjuvants. All of these features are desired in a good adjuvant.
To further reduce tissue reactions caused by adjuvants, CpG was shown to act synergistically even with lower doses of conventional adjuvants than are normally employed. For example, Emulsigen is an excellent adjuvant, but its use at the suggested concentration of 30% results in significant tissue damage at the site of vaccination. By lowering the Emulsigen percentage to 10% and combining it with CpG, it was possible to get the benefit of CpG and a balanced immune response with minimal tissue damage (Ioannou, unpublished) . Indeed, the magnitude and quality of the immune response with 10% Emulsigen Plus was equivalent to 30% Emulsigen plus CpG, but higher than 30% Emulsigen itself; 10% Emulsigen alone induced minimal immunity. In addition, by using CpG as an adjuvant, it was possible to reduce the quantity of antigen in the vaccine. This should prove to be a very important factor where quantities of vaccine are limited. For example, if we want to expand the doses of smallpox or foot-and-mouth disease vaccines by reducing the dose of antigen, this would be possible by using CpG as an adjuvant. Similarly, many recombinant proteins, especially those from viruses, are relatively expensive to produce and are in limited supply. The reason that recombinant viral glycoprotein are expensive to produce is that they require post-translational modification for retention of their conformational epitopes. These events generally only occur in mammalian or eukaryotic systems, thereby making production of these antigens expensive. Finally, CpG can increase the kinetics of development of the immune responses and, in some cases, can make poorly responsive animals respond to vaccination (Davis et al., 2000) . This has been clearly demonstrated in orangutans with hepatitis B, where some orangutans do not respond even after three immunizations with Enginex B. By combining CpG with hepatitis B vaccines, 100% of the animals responded after only two immunizations (Davis et al., 2000) .
Recent trends in vaccination have resulted in needlefree delivery systems for vaccine delivery. The reasons for this approach are twofold. First, needles are unpleasant and can be a source of disease transmission between individuals if the same needle is used repeatedly. Second, parenteral immunization does not induce effective mucosal immune responses. Since the majority of pathogens enter through mucosal surfaces, induction of immunity at mucosal surfaces should induce more effective protection. To this end, CpG was tested as a potential mucosal adjuvant. Numerous studies have clearly demonstrated that CpG can act as an excellent mucosal adjuvant (Moldoveanu et al., 1998; Davis, 1998, 2000) . Mucosal delivery of CpG induces a strong systemic Th1 response similar to the responses shown following parenteral immunization, but, in addition, produces a strong mucosal IgA response. Our contention is that mucosal vaccines and delivery systems will be safer than parenteral vaccines. The strong mucosal immune response should be more effective in not only preventing infection, but if infection occurs, the amount of pathogen shed into the environment will be reduced, thereby reducing the overall spread of the pathogen to cohorts. Finally, needlefree delivery of vaccines should increase compliance of vaccination, especially for humans, as the fear of needles has a significant impact on willingness to be vaccinated. Whether aerosol delivery of CpG to poultry will be effective remains a topic for further investigation.
CONCLUSIONS
Studies to date clearly demonstrate the potential of using CpG as both a stimulator of innate immunity as well as specific immunity to induce rapid (days) and long-term (weeks, months) protection from disease. By combining CpG with vaccines, it should be possible to increase the kinetics, magnitude, and the quality of the immune response to provide optimal protection for many infectious agents. Such approaches may provide sufficient levels of protection even after a single immunization. Such an approach should prove to be very economical and help to improve the health and welfare of numerous animal species including poultry. These developments clearly have the potential to dramatically alter management systems in animal husbandry.
